All Insight, Analysis and Views

ViewPoints: Sparing its energy, Aldeyra calls it quits in uveitis
Ref: ViewPoints Desk
Tags: ViewPointsAldeyra Therapeutics Clinical Research (R&D) Corporate Affairsreproxalap
ViewPoints: Almirall goes all-in on Dermira’s giant-hunting expedition
Ref: ViewPoints Desk
Tags: ViewPointsAlmirall Dermira Regeneron SanofiDermatitis FDAClinical Research (R&D) Licensing Marketing & SalesDupixent lebrikizumab
ViewPoints: A buyer’s guide to Otezla
Ref: ViewPoints Desk
Tags: ViewPointsCelgene BMSPsoriasis Medical AffairsOtezla
ViewPoints: AbbVie bets big on Botox's staying power
Ref: ViewPoints Desk
Tags: ViewPointsAbbVie Allergan Evolus Mylan Revance Corporate Affairs Marketing & SalesBotox DaxibotulinumtoxinA Humira Jeuveau
ViewPoints: AbbVie/Allergan - a deal built on Botox and inevitability
Ref: ViewPoints Desk
Tags: ViewPointsAbbVie Allergan Corporate Affairs Marketing & Sales Mergers & AcquisitionsBotox Humira
Physician Views snap poll results - More data support threat of JAK inhibitors to Dupixent in atopic dermatitis
Ref: Physician Views Desk
Tags: Physician Views Poll ResultsSanofi Regeneron Lilly PfizerDermatitis Clinical Research (R&D) Medical AffairsDupixent baricitinib abrocitinib
ViewPoints: Tazemetostat looking like a safer bet in 3L lymphoma
Ref: ViewPoints Desk
Tags: ViewPointsEpizyme Gilead BayerLymphomas FDAClinical Research (R&D) Marketing & Sales Medical Affairstazemetostat Zydelig Aliqopa
ViewPoints: Actions speak louder than words for Genfit
Ref: ViewPoints Desk
Tags: ViewPointsGenfit Terns Pharmaceuticals CymaBay TherapeuticsNonalcoholic steatohepatitis FDAClinical Research (R&D) Licensingelafibranor seladelpar
ViewPoints: Conatus, Novartis mourn the latest NASH programme death
Ref: ViewPoints Desk
Tags: ViewPointsConatus NovartisNonalcoholic steatohepatitis Clinical Research (R&D) Corporate Affairsemricasan
Physician Views Poll Results: Xeljanz down but far from out as safety concerns squeeze use in UC
Ref: Physician Views Desk
Tags: Physician Views Poll ResultsPfizerIBD EMAClinical Research (R&D) Medical AffairsXeljanz